Full Product Name
ALS2 siRNA (Rat)
Product Synonym Names
Alsin; Amyotrophic lateral sclerosis 2 protein homolog
Product Gene Name
ALS2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P0C5Y8
Specificity
ALS2 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat ALS2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ALS2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ALS2 sirna
siRNA to inhibit ALS2 expression using RNA interference
Applications Tested/Suitable for ALS2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ALS2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001013431.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001013413.1
[Other Products]
UniProt Primary Accession #
P0C5Y8
[Other Products]
UniProt Related Accession #
P0C5Y8[Other Products]
Molecular Weight
182,448 Da
NCBI Official Full Name
alsin
NCBI Official Synonym Full Names
amyotrophic lateral sclerosis 2 (juvenile)
NCBI Official Symbol
Als2??[Similar Products]
NCBI Protein Information
alsin
UniProt Protein Name
Alsin
UniProt Synonym Protein Names
Amyotrophic lateral sclerosis 2 protein homolog
UniProt Gene Name
Als2??[Similar Products]
UniProt Entry Name
ALS2_RAT
UniProt Comments for ALS2
ALS2: May act as a GTPase regulator. Controls survival and growth of spinal motoneurons. Defects in ALS2 are the cause of amyotrophic lateral sclerosis type 2 (ALS2). ALS2 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms. Defects in ALS2 are the cause of juvenile primary lateral sclerosis (JPLS). JPLS is a neurodegenerative disorder which is closely related to but clinically distinct from amyotrophic lateral sclerosis. It is a progressive paralytic disorder which results from dysfunction of the upper motor neurons of the motor cortex while the lower neurons are unaffected. Defects in ALS2 are the cause of infantile-onset ascending spastic paralysis (IAHSP). IAHSP is characterized by progressive spasticity and weakness of limbs. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: GEFs; GEFs, Rab
Cellular Component: centrosome; neuron projection; protein complex; intracellular membrane-bound organelle; cell; dendrite; postsynaptic density; early endosome; dendritic spine; cytosol; ruffle; growth cone; cell soma; membrane; axon; lamellipodium; cytoplasm; intracellular; vesicle
Molecular Function: protein serine/threonine kinase activator activity; Rho guanyl-nucleotide exchange factor activity; protein homodimerization activity; Rac guanyl-nucleotide exchange factor activity; guanyl-nucleotide exchange factor activity; Rab guanyl-nucleotide exchange factor activity; Rab GTPase binding
Biological Process: cell death; receptor recycling; synaptic transmission, glutamatergic; behavioral fear response; endosome organization and biogenesis; in utero embryonic development; vesicle organization and biogenesis; Rac protein signal transduction; locomotory behavior; endosome transport; protein localization; regulation of endosome size; axonogenesis; positive regulation of protein kinase activity; response to oxidative stress; neuromuscular junction development; neurite morphogenesis
Research Articles on ALS2
1. Als2 gene encodes a large protein termed alsin, which contains a number of predicted cell signaling and protein trafficking sequence motifs.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
